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Abstract
Background Blood transfusion is linked to a negative outcome for malignant tumors. The aim of this study was to evaluate
aggressive surgical resection for hilar cholangiocarcinoma (HCCA) and assess the impact of perioperative blood transfusion on
long-term survival.
Methods Sixty-six consecutive major hepatectomies with en bloc resection of the caudate lobe and extrahepatic bile duct for
HCCAwere performed using macroscopically curative resection at our institute from 2002 to 2012. Clinicopathologic factors for
recurrence and survival were retrospectively assessed.
Results Overall survival rates at 1, 3, and 5 years were 86.7, 47.3, and 35.7 %, respectively. In univariate analysis, perioperative
blood transfusion and a histological positive margin were two of several variables found to be significant prognostic factors for
recurrence or survival (P<0.05). In multivariate analysis, only perioperative blood transfusion was independently associated with
recurrence (hazard ratio (HR)=2.839 (95 % confidence interval (CI), 1.370–5.884), P=0.005), while perioperative blood trans-
fusion (HR=3.383 (95 % CI, 1.499–7.637), P=0.003) and R1 resection (HR=3.125 (95 % CI, 1.025–9.530), P=0.045) were
independent risk factors for poor survival.
Conclusions Perioperative blood transfusion is a strong predictor of poor survival after radical hepatectomy for HCCA.We suggest
that circumvention of perioperative blood transfusion can play an important role in long-term survival for patients with HCCA.
Keywords Hilar cholangiocarcinoma . Aggressive surgery .
Hepatectomy . Prognosis . Blood transfusion
Introduction
Surgical resection1,2 or liver transplantation3 remains the only
curative treatment that can offer long-term survival for hilar
cholangiocarcinoma (HCCA). HCCA involves the confluence
of the bilateral hepatic ducts where the main portal and hepatic
arterial branches are close, and thus major hepatectomy is
often required to obtain a disease-free margin status.
Simultaneous caudate lobectomy with extended resection of
the hilar bile ducts is now the procedure of choice because the
bile ducts of the caudate lobe are direct tributaries from the
bilateral hepatic ducts.4,5 In fact, several reports have shown
that hepatectomy with en bloc resection of the caudate lobe
and extrahepatic bile duct,6,7 lymph node dissection,8 or re-
section of portal vein9,10 or hepatic artery11,12 for HCCA is
more likely to result in disease-free resection. Preoperative
percutaneous transhepatic portal vein embolization (PTPVE)
has also helped to make major hepatectomy safer and appli-
cable to more patients.13
–18
Despite these preoperative and surgical advances for
achieving disease-free resection, many patients still have mi-
croscopic positive resection margins. This is of concern
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because margin status is a critical prognostic factor and cases
with microscopic invasive carcinoma at the ductal margin
have poor survival.6,7,16,17,19 However, aggressive and com-
plex procedures such as hepatectomywith en bloc resection of
the caudate lobe and extrahepatic bile duct for HCCA cause
excessive intraoperative loss of blood that requires periopera-
tive blood transfusion, which may also result in negative out-
comes for malignant tumors of the liver.20 However, the ef-
fects of blood transfusion on survival after aggressive surgery
for HCCA have not been widely studied.
In this study, we surveyed retrospective data in 66 consec-
utive hepatectomies with en bloc resection of the caudate lobe
and extrahepatic bile duct for HCCA performed at our insti-
tute. The main aim was to identify prognostic factors for re-
currence and long-term survival after aggressive surgery for




Between January 2002 and December 2012, 108 patients with
HCCA we r e a dm i t t e d t o t h e D e p a r tm e n t o f
Gastroenterological Surgery at Hirosaki University Hospital.
Nineteen patients did not undergo any surgery due to highly
advanced unresectable disease or poor liver function during
preoperative workup. Laparotomy was conducted in the re-
maining 89 patients. Twenty-three of the patients were exclud-
ed because three patients underwent minor hepatic resection
(only segment 4) with caudate lobe and extrahepatic bile duct;
one patient had R2 (macroscopic residual tumor) despite left
hepatectomy with caudate lobe and extrahepatic bile duct;
nine patients underwent palliative bile duct resection; two pa-
tients underwent palliative pancreatoduodenectomy; and eight
patients were not able to undergo resection due to liver metas-
tases or intraoperative detection of highly local advanced dis-
ease. The remaining 66 patents underwent major hepatecto-
mies (hemihepatectomy, central bisectionectomy, or more ex-
tensive resection) with en bloc resection of the caudate lobe
and extrahepatic bile duct in addition to macroscopically cu-
rative resection (R0 or R1 resection) were enrolled in this
study. HCCA was defined as a tumor involving the primary
ductal confluence. Tumors invading the hepatic hilar region
but located predominantly in the liver parenchyma and gall
bladder were not included in the definition of HCCA. All
clinical information was collected based on prospectively
maintained data and analyzed retrospectively. Demographic
data included information on gender, age, mode of presenta-
tion, pre-resection interventions, and investigations.
Preoperative laboratory values included serum carbohydrate
antigen 19-9 (CA19-9) as a tumor marker and indocyanine
green retention value at 15 min (indocyanine green (ICG)-
R15) as a marker of hepatic function reserve. Operative re-
cords were reviewed for operative details, operative time, in-
traoperative estimated blood loss, and blood transfusion
requirements.
Preoperative Evaluation and Workup
The location and extent of the disease were evaluated by ul-
trasonography, enhanced computed tomography (CT), mag-
netic resonance imaging (MRI) with magnetic resonance
cholangiopancreatography (MRCP), endoscopic retrograde
cholangiography (ERC), and percutaneous transhepatic chol-
angiography (PTC). Enhanced CT was performed before bil-
iary drainage, which in turn was performed if obstructive jaun-
dice (total bilirubin (T-bil) >3 mg/dL) was present.
Endoscopic biliary drainage (EBD) was preferred, but percu-
taneous transhepatic biliary drainage (PTBD) was performed
when EBD was not successful. Biliary drainage was per-
formed primarily for the future liver remnant (FLR) lobe;
however, in cases of bilateral biliary sepsis, both lobes were
drained. Biliary drainage was undertaken until T-bil decreased
to <2 mg/dL. In patients with cholangitis, surgery was post-
poned until alleviation of inflammation. Enhanced CT of the
chest, abdomen, and pelvis was used to identify metastatic
lesions. More recently, positron emission tomography (PET)
has also been used for this purpose. Unresectable disease was
defined as the presence of extensive bilobular metastases or
extrahepatic metastases other than regional lymph node in-
volvement or peritoneal dissemination.
The total liver volume (TLV) and the part of the hepatic
segment to be resected were calculated using CT volumetry.21
PTPVE was indicated when the FLR was estimated to be
<40 % and was performed 3 to 4 weeks before scheduled liver
resection, since PTPVE has been suggested to be useful for
inducing compensatory hypertrophy of the FLR.13 All pa-
tients underwent CT within 4 weeks after PTPVE. ICG tests
were performed in all cases before surgery. For patients who
underwent PTPVE, ICG tests were performed just before and
3 to 4 weeks after PTPVE. ICG (0.5 mg/kg body weight) was
administered via a peripheral vein and venous blood was sam-
pled before and 5, 10, and 15 min after injection. The plasma
clearance rate of ICG (KICG) was calculated by linear regres-
sion analysis of plasma ICG concentrations.22 Total liver func-
tion was evaluated based on KICG, and the KICG of the FLR
was calculated using the following formula: KICG×FLR vol-
ume/TLV.18
Surgical Technique
All operations were performed after T-bil had decreased to
<2 mg/dL. Preoperative autologous blood donation was per-
formed in patients with preoperative hemoglobin level of
J Gastrointest Surg (2015) 19:866–879 867
>11 g/dL and no hypotension or severe cardiac disease, at the
discretion of the anesthesiologist. Firstly, en bloc dissection of
the regional lymph nodes surrounding the hepatoduodenal
ligament, behind the pancreatic head, and around the common
hepatic artery was uniformly performed, followed by
skeletonization of the hepatic hilus. After complete mobiliza-
tion of the hepatic lobe to be resected, the caudate lobe was
completely separated from the inferior vena cava. Liver transec-
tion was carried out using CUSA (Aloka, Tokyo, Japan) or the
forceps clamp-crushing method based on the surgeon’s prefer-
ence during hepatic artery and portal vein clamping for 15 min
with 5-min intervals, which is known as Pringle’s maneuver. All
patients underwent hemihepatectomy, central bisectionectomy,
ormore extensive resectionwith en bloc resection of the caudate
lobe and extrahepatic bile duct. Biliary continuity was recon-
structed with hepaticojejunostomy using a Roux-en-Y jejunal
limb brought up in a transmesenteric fashion. Combined
pancreatoduodenectomy was performed if the tumor extended
below the intrapancreatic portion of the distal bile duct.23
Reconstruction for hepatopancreatoduodenectomy was con-
ducted by a modified Child’s method with an end-to-side anas-
tomosis. Concomitant portal vein resection and reconstruction
have been applied aggressively in cases with suspected macro-
scopic invasion during surgery.9,10 Concomitant hepatic artery
resection and reconstruction have been similarly applied, al-
though this is still controversial.11,12,24
–26 All autologous blood
collected preoperatively was transfused intraoperatively.
Allogeneic red blood cells and fresh frozen plasma (FFP) were
transfused intraoperatively at the discretion of the
anesthesiologist.
Histopathological Evaluation
Pathology reports were reviewed to determine tumor histolog-
ical grade, margin status, and the presence of microvascular,
lymphovascular and perineural invasion. Tumors were staged
using the tumor-node-metastasis (TNM) Classification of
Malignant Tumors of the International Union Against Cancer
(7th edition, 2009) for proximal extrahepatic bile duct cancer.27
Therefore, intrahepatic metastasis, peritoneal deposits and pos-
itive para-aortic nodes were classified as distant metastasis
(M1). R0 resection was defined as negative ductal and radial
margins on histology; R1 resection as the histological presence
of a tumor at any margin; and R2 resection as the macroscopic
presence of a tumor at any margin or M1. Histopathological
evidence of invasive carcinoma, dysplastic lesions including
carcinoma in situ (CIS), or normal epithelium was recorded
for proximal and distal ductal margins. Radial margins were
assessed in the resected specimen only. Dysplastic lesions and
CIS were defined as R0 resection because it is difficult to dis-
tinguish CIS from high-grade dysplastic lesions pathological-
ly,28 and the presence of CIS at the ductal margin has no impact




Patients were not routinely admitted to the intensive care
unit postoperatively but were monitored overnight in the
general ward. In principle, allogeneic red blood cell trans-
fusion was performed for asymptomatic patients if the
hemoglobin level fell to <6.5 g/dL. However, patients
with additional specific risk factors such as severe cardiac
disease or hypotension often received blood transfusion
when the hemoglobin level fell to <7 g/dL. FFP was used
at the discretion of the attending surgeon and was most
commonly administered for prothrombin time (PT)
<60 %. Liver function tests were obtained routinely on
postoperative days 1, 3, and 6 and as clinically indicated
thereafter. Hepatic failure was defined as T-bil of
>7.0 mg/dL postoperatively, and hyperbilirubinemia was
defined as T-bil of >5.0 mg/dL.35 Hence, the postopera-
tive maximum T-bil and minimum PT were assessed.
Postoperative complications were defined and graded ac-
cording to the validated Clavien classification system36 as
grades 1 and 2 and grades 3–5 for minor and major com-
plications, respectively. Postoperative mortality was de-
fined as death as an inpatient or within 30 days of surgery.
Adjuvant Treatment
Since 2008, all patients except UICC stage I cases were
scheduled to receive S-1, an oral fluoropyrimidine de-
rivative, as adjuvant chemotherapy for about 1 year fol-
lowing surgery, whereas those prior to 2007 did not
receive chemotherapy.
Follow-up After Surgical Resection
Patients were followed regularly at the outpatient clinic every
1–3 months. Clinical examinations were performed, tumor
markers (carcinoembryonic antigen and CA19-9) and liver
function were checked monthly, and CT scans of the chest,
abdomen, and pelvis were performed every 3 months until
year 2. Thereafter, clinical examinations, tumor marker tests,
liver function tests, and CT scans were carried out every
6 months until year 5. Subsequently, patients attended a clinic
for an annual examination. MRI and PET-CTwere carried out
if recurrence was suspected in routine follow-up.
Survival and Prognostic Factors
The following data were reviewed to identify prognostic fac-
tors: (1) preoperative clinical factors: gender, age, jaundice,
preoperative CA19-9 value, preoperative ICG-R15, FLR
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Table 1 Patient characteristics and outcomes
Total (n=66) No transfusion (n=37) Transfusion (n=29) P value
Gender
Male 43 (65.2 %) 21 (72.4 %) 22 (59.5 %) 0.273b
Female 23 (34.8 %) 8 (27.6 %) 15 (40.5 %)
Age 68.5 (39–80) 66 (39–79) 70 (42–80) 0.096a
Preoperative jaundice
No 19 (28.8 %) 14 (37.8 %) 5 (17.2 %) 0.067b
Yes 47 (71.2 %) 23 (62.2 %) 24 (82.8 %)
Preoperative serum value
CA19-9 (U/mL) 38.5 (3–14,567) 20 (3–14,567) 62 (3–6666) 0.039a, *
ICG-R15 (%) 10.75 (0.1–43) 10.8 (0.7–43.0) 9.0 (0.1–32.9) 0.574a
FLR ratio (%) 47.5 (25.1–86.3) 46.5 (25.1–86.3) 50.4 (33.4–77.0) 0.179a
KICG of FLR 0.070 (0.021–0.323) 0.069 (0.021–0.179) 0.073 (0.028–0.323) 0.275a
Preoperative PTPVE
No 34 (51.5 %) 21 (56.8 %) 13 (44.8 %) 0.336b
Yes 32 (48.5 %) 16 (43.2 %) 16 (55.2 %)
Operative details
Right hepatectomy 43 (65.2 %) 24 (64.9 %) 19 (65.5 %) 0.337b
Left hepatectomy 19 (28.8 %) 9 (24.3 %) 10 (34.5 %)
Right trisectionectomy 3 (4.5 %) 3 (8.1 %) 0 (0.0 %)
Central bisectionectomy 1 (1.5 %) 1 (2.7 %) 0 (0.0 %)
Operative time (min) 500.5 (307–710) 470 (307–670) 590 (390–710) <0.001a, *
Operative blood loss (mL) 1778.5 (250–11,170) 1380 (250–2800) 2910 (990–11,170) <0.001a, *
Postoperative complication (Clavien–Dindo classification)
Grade 0 4 (6.1 %) 4 (10.8 %) 0 (0.0 %) 0.197b
Grade 1 9 (13.6 %) 7 (18.9 %) 2 (6.9 %)
Grade 2 22 (33.3 %) 10 (27.0 %) 12 (41.4 %)
Grade 3 26 (39.4 %) 14 (37.8 %) 12 (41.4 %)
Grade 4 4 (6.1 %) 2 (5.4 %) 2 (6.9 %)
Grade 5 (Hospital death) 1 (1.5 %) 0 (0.0 %) 1 (3.4 %)
Postoperative max. T-bil (mg/dL) 3.55 (1.4–14.7) 2.8 (1.4–10.4) 4.8 (2.0–14.7) <0.001a, *
Postoperative min. PT (%) 66.5 (34–93) 68 (38–93) 62 (34–89) 0.130a
Adjuvant chemotherapy
Yes 30 (45.5 %) 20 (54.1 %) 10 (34.5 %) 0.113b
No 36 (54.5 %) 17 (45.9 %) 19 (65.5 %)
T-stage (UICC)
T1 4 (6.1 %) 3 (8.1 %) 1 (3.4 %) 0.542b
T2a 22 (33.3 %) 14 (37.8 %) 8 (27.6 %)
T2b 21 (31.8 %) 11 (29.7 %) 10 (34.5 %)
T3 12 (18.2 %) 7 (18.9 %) 5 (17.2 %)
T4 7 (10.6 %) 2 (5.4 %) 5 (17.2 %)
Lymph node status
Negative 44 (66.7 %) 27 (73.0 %) 17 (58.6 %) 0.220b
Positive 22 (33.3 %) 10 (27.0 %) 12 (41.4 %)
Tumor histological grade
Papillary/well differentiated 16 (24.2 %) 8 (21.6 %) 8 (27.6 %) 0.575b
Moderate/poorly differentiated 50 (75.8 %) 29 (78.4 %) 21 (72.4 %)
Microvascular invasion
Negative 18 (27.3 %) 11 (29.7 %) 7 (24.1 %) 0.613b
Positive 48 (72.7 %) 26 (70.3 %) 22 (75.9 %)
Lymphovascular invasion
Negative 10 (15.2 %) 8 (21.6 %) 2 (6.9 %) 0.093b
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ratio, KICG of the FLR, and preoperative PTPVE; (2)
treatment-related factors: operative procedure, operative time,
operative blood loss, perioperative blood transfusion (except
for autologous blood transfusion), postoperative complica-
tion, postoperative maximum T-bil, postoperative minimum
PT, and adjuvant chemotherapy; and (3) pathologic factors:
T-stage (UICC), lymph node metastasis, tumor histological
grade, microvascular invasion, lymphovascular invasion, peri-
neural invasion, and resection margin status.
Disease-free survival (DFS) was defined as the time
from the operation to the date of disease recurrence.
Overall survival (OS) was defined as the time from
the operation to the time of death due to recurrence or
the last follow-up time.
Statistical Analysis
For variables associated with perioperative blood transfu-
sion, continuous variables are expressed as median and
interquartile range and were compared by Mann–
Whitney U test, and categorical variables were compared
by Pearson Chi-square test with a Fisher exact test or
Yates continuity correction where appropriate in univari-
ate analysis. Variables with a significant relationship with
perioperative blood transfusion in univariate analysis were
used in a multivariate logistic regression model. DFS and
OS were calculated by the Kaplan–Meier method, and
differences were evaluated by log-rank test. Only vari-
ables that were significant in univariate analysis were in-
cluded in multivariate analysis to identify independent
predictors of DFS and OS. This analysis was performed
using a Cox proportional hazards regression model.
P<0.05 was considered significant in all analyses. All
analyses were performed using PASW Statistics ver.18.0
for Windows (SPSS, Inc., Chicago, IL, USA).
Results
Patient Characteristics and Preoperative Management
The characteristics of the 66 patients (43 males, 23 fe-
males) are summarized in Table 1. The patients had a
median age of 68.5 years (range, 39–80 years), and all
underwent major hepatectomy with en bloc resection of
the caudate lobe and extrahepatic bile duct for HCCA.
Jaundice at initial presentation was present in 47 patients
(71.2 %). Biliary drainage was performed in 60 patients
(90.9 %), including 13 nonjaundiced patients who
underwent biliary drainage to relieve cholangitis or to
determine the extent of a lesion along the individual
intrahepatic segmental duct. EBD, PTBD, and both EBD
and PTBD were performed in 32 (53.3 %), 24 (40.0 %),
and 4 cases (6.7 %), respectively. The median CA 19-9
value was 38.5 U/mL (range, 3–14,567 U/mL), and the
median ICG-R15 was 10.8 % (0.1–43 %). The median
FLR ratio and KICG of FLR were 47.5 % and 0.070,
respectively. PTPVE was carried out in 32 patients
(48.5 %).
Table 1 (continued)
Total (n=66) No transfusion (n=37) Transfusion (n=29) P value
Positive 56 (84.8 %) 29 (78.4 %) 27 (93.1 %)
Perineural invasion
Negative 10 (15.2 %) 7 (18.9 %) 3 (10.3 %) 0.271b
Positive 56 (84.8 %) 30 (81.1 %) 26 (89.7 %)
Margin status
R0 54 (81.8 %) 32 (86.5 %) 22 (75.9 %) 0.267b
R1 12 (18.2 %) 5 (13.5 %) 7 (24.1 %)
Values are presented as n (%) or median (range)
ICG-R15 indocyanine green retention rate at 15 min, FLR future liver remnant, KICG indocyanine green clearance rate, PTPVE percutaneous




Table 2 Significant factor for perioperative blood transfusion in
multivariate analysis
Variable Odds ratio 95 % CI P value
Preoperative CA19-9 value (U/mL) 1.000 0.999–1.000 0.337
Operative time (min) 1.002 0.994–1.011 0.583




95% CI 95 % confidence interval
*P<0.05
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Table 3 Clinicopathological features predicting disease-free survival
Variable Number 3-year DFS (%) MST (month) Univariate analysis Multivariate analysis
P value RR 95 % CI P value
Gender
Male 43 32.9 15.1 0.027* 2.007 0.849–4.748 0.113
Female 23 54.9 36.5
Age
≤70 years 42 41.9 17.9 0.543
>70 years 24 34.4 20.3
Preoperative jaundice
No 19 50.0 26.4 0.118
Yes 47 35.7 16.3
Preoperative serum CA19-9
≤37 U/mL 32 61.7 39.1 0.004* 1.903 0.834–4.339 0.126
>37 U/mL 34 17.9 12.3
Preoperative ICG-R15
≤15 % 48 49.0 26.4 0.063
>15 % 18 17.4 15.1
FLR ratio
>40 % 50 39.3 20.3 0.976
≤40 % 16 43.8 17.9
KICG of FLR
>0.05 53 42.5 20.2 0.356
≤0.05 13 31.7 17.7
Preoperative PTPVE
No 34 51.9 36.5 0.029* 0.899 0.376–2.150 0.811
Yes 32 27.4 12.9
Liver resection
Left 19 61.1 48.8 0.038* 1.518 0.527–4.368 0.439
Righta 47 30.6 15.6
Operative time
≤480 min 28 37.8 20.3 0.819
>480 min 38 42.3 16.3
Operative blood loss
≤1500 mL 26 47.7 35.8 0.245
>1500 mL 40 37.3 14.8
Perioperative blood transfusion
No 37 50.9 37.2 0.007* 2.839 1.370–5.884 0.005*
Yes 29 24.9 12.3
Postoperative complication (Clavien–Dindo classification)
Grades 0–2 35 47.0 35.8 0.055
Grades 3–5 31 32.1 12.3
Postoperative max. T-bil
≤5.0 mg/dL 47 50.7 36.5 0.026* 0.655 0.292–1.467 0.304
>5.0 mg/dL 19 9.4 15.1
Postoperative min. PT
>60 % 46 37.9 20.3 0.964
≤60 % 20 49.0 17.9
Adjuvant chemotherapy
Yes 30 37.8 20.3 0.802
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Treatment-Related Characteristics
The operative procedures included right hepatectomy (n=43),
left hepatectomy (n=19), right trisectionectomy (n=3), and cen-
tral bisectionectomy (n=1) with en bloc resection of the caudate
lobe and extrahepatic bile duct. No patients underwent left
trisectionectomy. Portal vein resection and hepatic artery resec-
tion were required in 11 (16.7 %) and 1 case (1.5 %), respective-
ly, and seven patients (10.6 %) underwent combined
pancreatoduodenectomy. The median operative time was
500.5 min (range, 307–710 min), and the median estimated
blood loss was 1778.5 mL (range, 250–11,170 mL).
Perioperative allogeneic red blood cell transfusion was per-
formed in 29 patients (43.9 %). Postoperative major complica-
tions occurred in 31 patients (47 %), with intra-abdominal ab-
scess requiring percutaneous drainage being the most frequent
complication, occurring in 19 patients. Bile leakage from the
liver transection surface, severe ascites, hepaticojejunostomy in-
sufficiency, and pleural effusion requiring an invasive
intervention occurred in 11, 10, 9, and 8 patients, respectively.
In two patients, radiologic intervention was performed due to
postoperative bleeding from pseudoaneurysm of the hepatic ar-
tery. The mortality rate was 1.5 % (one patient), and this patient
died of sepsis related to intra-abdominal abscesswith breakdown
of hepaticojejunostomy. The postoperative maximum T-bil was
3.6 mg/dL (range, 1.4–14.7 mg/dL), with 12 patients diagnosed
with hepatic failure and 19 with hyperbilirubinemia. The post-
operative minimum PTwas 66.5 % (range, 34–93 %). Adjuvant
chemotherapywas given postoperatively in 30 patients (45.5%),
using S-1 and gemcitabine in 28 and 2 patients, respectively.
Tumor Characteristics
Four patients (6.1 %) had stage T1 disease, 22 (33.3 %) had
T2a, 21 (31.8 %) had T2b, 12 (18.2 %) had T3, and 7 (10.6 %)
had T4. Lymph node infiltration was noted in 22 patients
(33.3 %). For the histological tumor grade, papillary or well-
differentiated adenocarcinomas were found in 16 patients
Table 3 (continued)
Variable Number 3-year DFS (%) MST (month) Univariate analysis Multivariate analysis
P value RR 95 % CI P value
No 36 41.3 26.3
T-stage (UICC)
T1, T2 47 45.3 26.3 0.116
T3, T4 19 24.1 15.1
Lymph node status
Negative 44 49.7 35.8 0.001* 1.832 0.796–4.213 0.154
Positive 22 21.9 6.8
Tumor histological grade





Negative 18 62.5 92.9 0.005* 2.620 0.841–8.166 0.097
Positive 48 31.6 15.1
Lymphovascular invasion
Negative 10 60.0 NR 0.048* 0.608 0.159–2.328 0.468
Positive 56 36.3 16.3
Perineural invasion
Negative 10 55.6 92.9 0.148
Positive 56 38.0 15.6
Margin status
R0 54 43.5 26.4 0.091
R1 12 24.9 12.9
DFS disease-free survival, MST median survival time, RR risk ratio, 95 % CI 95 % confidence interval, ICG-R15 indocyanine green retention rate at
15 min, FLR future liver remnant, KICG indocyanine green clearance rate, PTPVE percutaneous transhepatic portal vein embolization, T-bil total
bilirubin, PT prothrombin time, UICC Union for International Cancer Control
*P<0.05
a Including three right trisectionectomy and one central bisectionectomy
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(24.2 %) and moderate or poorly differentiated tumors were
present in 50 (75.8 %). Microvascular, lymphovascular, and
perineural invasion were seen in 48 (72.7 %), 56 (84.5 %), and
56 (84.8 %) patients, respectively. R0 resection was achieved
in 54 patients (81.8 %) and R1 resection in 12 (18.2 %).
Risk Factors for Perioperative Blood Transfusion
Of the 66 patients, 29 (43.9 %) and 37 (56.1 %) did and did
not receive perioperative allogeneic red blood cell transfusion,
respectively. A median of 4 blood units were transfused
(range, 1–32 units). The clinical, operative, and pathological
differences between these two groups of patients are shown in
Table 1. Blood transfusion was more frequent in patients with
a high preoperative CA19-9 level (median, 62 vs. 20 U/mL,
P=0.039). Patients who received blood transfusion also had
longer operation times (median, 590 vs. 470 min, P<0.001),
higher estimated blood loss (median, 2910 vs. 1380 mL,
P<0.001), and higher postoperative maximum T-bil (median,
4.8 vs. 2.8 mg/dL, P<0.001). In multivariate analysis, only
the estimated blood loss was independently associated with
blood transfusion (odds ratio=1.002 (95 % confidence inter-
val (CI), 1.001–1.003), P=0.002) (Table 2).
Survival Analysis
The median follow-up was 23.0 months (range, 1.2–
109.0 months). OS rates at 1, 3, and 5 years for the entire
cohort were 86.7, 47.3, and 35.7 %, respectively, with a me-
dian OS of 31.7 months. The 1-, 3-, and 5-year DFS rates for
the same populationwere 66.3, 40.5, and 30.6%, respectively,
with a median DFS of 20.3 months.
The clinical, operative and pathological factors influencing
DFS are shown in Table 3. In univariate analysis, significant
predictors of decreased DFS were male gender (P=0.027),
preoperative CA19-9 >37 U/mL (P=0.004), preoperative
PTPVE (P=0.029), operative procedures except for left hep-
atectomy (P=0.038), perioperative blood transfusion (P=
0.007), postoperative maximum T-bil >5.0 mg/dL (P=
0.026), positive lymph node (P=0.001), microvascular inva-
sion (P=0.005), and lymphovascular invasion (P=0.048). In
multivariate analysis, perioperative blood transfusion was the
only independent prognostic factor for DFS (hazard ratio
(HR)=2.839, 95 % CI 1.370–5.884, P=0.005). Kaplan–
Meier survival curves gave median times to recurrence after
resection of 12.3 and 37.2 months with and without blood
transfusion, respectively (Fig. 1).
The clinical, operative and pathological factors influencing
OS are shown in Table 4. In univariate analysis, significant
predictors of decreased OS were male gender (P=0.033), pre-
operative jaundice (P=0.010), preoperative CA19-9 >37 U/
mL (P=0.004), preoperative PTPVE (P=0.035), operative
procedures except for left hepatectomy (P=0.024),
perioperative blood transfusion (P=0.002), postoperative
maximum T-bil >5.0 mg/dL (P=0.002), T3/T4 stage (P=
0.014), positive lymph node (P=0.035), microvascular inva-
sion (P=0.005), lymphovascular invasion (P=0.043), and
positive resection margin (P=0.002). In multivariate analysis,
perioperative blood transfusion (HR=3.383 (95 % CI, 1.499–
7.637), P=0.002) and a positive resection margin (HR=3.125
(95 % CI, 1.025–9.530), P=0.045) were independent prog-
nostic factors for OS. Kaplan–Meier survival curves gave
median OS times after resection of 20.1 and 74.3 months
with and without blood transfusion, respectively
(Fig. 2).
Discussion
HCCA is a rare cancer with an estimated incidence of 0.8 and
1.2 per 100,000 in females and males, respectively. Recent
developments in surgical techniques and perioperative man-
agement have led to a significant improvement in the resect-
ability rate and survival for HCCA, but morbidity and a poor
prognosis are still of concern. However, complete surgical
removal of cancer tissues by surgical resection or liver trans-
plantation is the only curative treatment, since there is no
evidence of efficacy of chemotherapy or radiotherapy. In a
recent review of reports of surgical resection for HCCA, Ito
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Fig. 1 Disease-free survival curves for patients after aggressive surgical
resection for hilar cholangiocarcinoma stratified by perioperative
allogeneic red blood cell transfusion status. Median time to recurrence
of 37.2 months without transfusion vs. 12.3 months with transfusion,
P=0.007
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Table 4 Clinicopathological features predicting overall survival
Variable Number 5-year OS (%) MST (month) Univariate analysis Multivariate analysis
P value RR 95 % CI P value
Gender
Male 43 27.5 46.3 0.033* 1.519 0.524–4.399 0.441
Female 23 49.8 25.1
Age
≤70 years 42 47.4 56.4 0.280
>70 years 24 16.5 29.8
Preoperative jaundice
No 19 60.5 NR 0.010* 1.936 0.607–6.177 0.264
Yes 47 24.5 26.0
Preoperative serum CA19-9
≤37 U/mL 32 54.7 74.3 0.004* 2.070 0.803–5.337 0.132
>37 U/mL 34 14.9 26.0
Preoperative ICG-R15
≤15 % 48 47.4 46.3 0.097
>15 % 18 9.0 31.5
FLR ratio
>40 % 50 32.4 31.7 0.924
≤40 % 16 44.4 53.5
KICG of FLR
>0.05 53 42.3 31.7 0.196
≤0.05 13 20.0 24.3
Preoperative PTPVE
No 34 42.4 53.5 0.035* 0.962 0.376–2.463 0.936
Yes 32 28.8 23.1
Liver resection
Left 19 56.3 96.1 0.024* 2.332 0.628–8.668 0.206
Righta 47 25.1 28.2
Operative time
≤480 min 28 27.0 36.5 0.715
>480 min 38 40.0 31.5
Operative blood loss
≤1500 mL 26 47.1 56.4 0.083
>1500 mL 40 26.8 26.0
Perioperative blood transfusion
No 37 50.1 74.3 0.002* 3.383 1.499–7.637 0.003*
Yes 29 14.7 20.1
Postoperative complication (Clavien–Dindo classification)
Grades 0–2 35 42.5 53.5 0.065
Grades 3–5 31 27.8 22.9
Postoperative max. T-bil
≤5.0 mg/dL 47 48.6 53.5 0.002* 1.155 0.484–2.757 0.746
>5.0 mg/dL 19 0.0 23.1
Postoperative min. PT
>60 % 46 32.4 31.7 0.762
≤60 % 20 46.7 36.5
Adjuvant chemotherapy
Yes 30 24.3 26.0 0.914
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to 95 % and 11 to 45 %, respectively, with morbidity of 14 to
76 % and mortality of 0 to 19 %. In our study, the curative
resection rate using major hepatectomy with en bloc resection
of the caudate lobe and extrahepatic bile duct was 81.8 %,
which is relatively favorable compared with previous studies.
Similar, we found a somewhat favorable 5-year survival rate
of 35.7 %, morbidity of 47 %, and mortality of 1.5 % in the
current series.
Many clinicopathological factors, including positive mar-
gin status, lymph node involvement, higher T-stage, moderate
or poorly differentiated tumor grade, perineural invasion, mi-
crovascular invasion and lymphovascular invasion, can have a
negative impact on long-term outcome after resection for
HCCA.6,7,16,17,19,38
–46 Of these factors, a positive margin sta-
tus has frequently been identified as a risk factor associated
with reduced survival in patients with HCCA. Complete re-
section with negative histologic margins is the only modifi-
able factor among potential risk factors, and thus is the prima-
ry goal of surgical treatment.37 Aggressive surgery with
concomitant major hepatic resection is thought to be more
effective for acquisition of a negative margin, compared with
local resection.6,7,42,46,47 Consistent with this view, aggressive
surgery in this study resulted in a relatively high R0 resection
rate of 81.8 %, and cases with R0 resection had a significantly
better prognosis compared with those with R1 resection.
The current study also indicated that a requirement for
perioperative blood transfusion was a strong independent risk
factor for both recurrence and poor survival after surgical re-
section for HCCA. In addition, intraoperative blood loss was
significantly associated with blood transfusion requirements.
Allogeneic blood transfusions are known to induce host im-
munosuppression. Some older reports have suggested some
positive effects of blood transfusion, including a beneficial
effect on graft prolongation after renal transplantation48 and
reduction of recurrence of Crohn’s disease.49 In contrast, since
Burrows et al. first reported that blood transfusion was asso-
ciated with adverse oncologic outcomes after resection of co-
lorectal cancer,50 many negative effects of blood transfusion
Table 4 (continued)
Variable Number 5-year OS (%) MST (month) Univariate analysis Multivariate analysis
P value RR 95 % CI P value
No 36 36.0 31.7
T-stage (UICC)
T1, T2 47 48.8 36.5 0.014* 0.954 0.369–2.466 0.922
T3, T4 19 0.0 24.3
Lymph node status
Negative 44 41.4 46.3 0.035* 0.826 0.286–2.383 0.723
Positive 22 23.8 22.9
Tumor histological grade





Negative 18 68.2 96.1 0.005* 2.016 0.525–7.736 0.307
Positive 48 14.5 29.8
Lymphovascular invasion
Negative 10 70.0 NR 0.043* 0.380 0.065–2.221 0.283
Positive 56 27.8 27.8
Perineural invasion
Negative 10 64.8 96.1 0.129
Positive 56 29.1 31.5
Margin status
R0 54 42.3 36.5 0.002* 3.125 1.025–9.530 0.045*
R1 12 0.0 18.3
DFS disease-free survival, MST median survival time, RR risk ratio, 95 % CI 95 % confidence interval, ICG-R15 indocyanine green retention rate at
15 min, FLR future liver remnant, KICG indocyanine green clearance rate, PTPVE percutaneous transhepatic portal vein embolization, T-bil total
bilirubin, PT prothrombin time, UICC Union for International Cancer Control
*P<0.05
a Including three right trisectionectomy and one central bisectionectomy
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–65 Therefore, avoidance of unnecessary blood trans-
fusion is of particular clinical importance.
In liver surgery, there is a high incidence of blood transfu-
sion because intraoperative blood loss is often large.
Immunomodulation due to perioperative blood transfusion
has been linked to cancer recurrence, particularly in surgery
for hepatocellular carcinoma66
–71 and colorectal liver
metastases.72,73 However, developments in surgical tech-
niques, perioperative management, and anesthetic protocols
have markedly improved outcomes after liver surgery.74,75
Nevertheless, the procedure is often accompanied by substan-
tial intraoperative blood loss and a requirement for blood
transfusion perioperatively or in the postoperative course, es-
pecially in extended hepatectomy or surgery for liver
cirrhosis.
Few studies have focused on the negative impact of blood
transfusion on outcome after liver resection for HCCA. This
type of hepatectomy is more complex and difficult to perform
and more risky than that for hepatocellular carcinoma or liver
metastasis because concomitant extrahepatic bile duct resec-
tion with lymph node dissection and biliary reconstruction are
required for HCCA. This can lead to a large amount of blood
loss and a need for blood transfusion in comparison with sim-
ple hepatectomy. Thus, the median blood loss in the current
study was 1778.5 ml, which is a relatively large amount. A
few studies have found that perioperative blood transfusion is
a negative predictor for morbidity or mortality after resection
for HCCA.76
–78 The association between blood transfusion
and long-term survival after resection for HCCA has only
been examined in two previous studies,79,80 as far as we are
aware. In 40 patients undergoing surgical resection for
HCCA, Liu et al.79 found a significant association between
blood transfusion and poor survival in univariate analysis, but
blood transfusion could not be confirmed as an independent
predictor in multivariate analysis. In a recent study of 83 pa-
tients with HCCA, Young et al.80 found that perioperative
blood transfusion was a significant independent determinant
of reduced survival after surgery by multivariate analysis.
Similarly, in the present study, perioperative blood transfusion
was a strong independent predictor for recurrence and poor
survival after liver resection for HCCA. Thus, this studymight
be thought of as the second to show a significant independent
correlation between blood transfusion and prognosis in pa-
tients with HCCA. One difference between this study and that
of Young et al.80 is that all of our patients underwent major
hepatectomy with caudate lobe and extrahepatic bile duct re-
section, whereas Young et al. included patients who
underwent local resection alone, in addition to cases treated
with aggressive surgery.80
The mechanism underlying the adverse effect of blood
transfusion is unclear, but experimental and clinical studies
have demonstrated that blood transfusion suppresses host im-
munity via reduction of natural killer cell activity and cytotox-
ic T cell function, increases suppressor T cell activity, and
decrease helper/suppressor (T4/T8) lymphocyte ratios.81,82
Also, leaching of biologically active substance from cells into
stored blood products occurs due to normal physiological ag-
ing and metabolic processes, and these leached bioactive sub-
stances have immunomodulatory effects that promote cell
growth and angiogenesis, and may therefore have a direct
effect on tumor growth.83 For this reason, the immunosup-
pressive effect of blood transfusion may play a major role in
recurrence of a malignant tumor. Goeppert et al. recently
showed that the presence of both intratumoral T and B lym-
phocytes is correlated with longer survival in cholangiocarci-
noma, and that the prognosis was linked to inflammation.
These data provide a solid basis for the understanding of the
biological role of inflammatory infiltrates in cholangiocarci-
noma and for functional and clinical studies exploring modu-
lation of the inflammatory response in cholangiocarcinoma
patients.84 The results indicate that an immunosuppressive
status may affect recurrence and survival in patients with chol-
angiocarcinoma, even though the adverse effects of blood
transfusion on host immunity are still unclear.
The current study has several limitations. First, it was per-
formed retrospectively and not as a randomized controlled
study, and included a relatively small number of patients
who received blood transfusion. However, it is very difficult
to design a prospective randomized trial to investigate the
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Fig. 2 Overall survival curves for patients after aggressive surgical
resection for hilar cholangiocarcinoma stratified by perioperative
allogeneic red blood cell transfusion status. Median survival time of
74.3 months without transfusion vs. 20.1 months with transfusion,
P=0.002
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Second, we did not analyze the association between transfu-
sion quantity and survival because the small sample size of
patients receiving blood transfusion may have resulted in a
loss of statistical power. Third, we also did not analyze the
influence of perioperative FFP transfusion on HCCA progno-
sis because almost all patients received administration of FFP
during surgery or within at least 7 days postoperatively.
In summary, we identified perioperative blood transfusion
and a histologic positive margin as strong independent predic-
tors for a poor prognosis following aggressive surgery with
concomitant major hepatectomy for HCCA. Thus, circumven-
tion of perioperative blood transfusion is likely to play an
important role in long-term survival for patients with
HCCA. It is widely believed that an aggressive surgical ap-
proach to gain a negativemargin is associated with a favorable
prognosis. However, better long-term survival may be
achieved through vigilant surgery to reduce blood loss and
avoid blood transfusion when possible. More effective preop-
erative or postoperative adjuvant therapy and surgery for on-
cological control of advanced HCCA is also required to im-
prove future outcomes.
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